EP 220: Turning human brain physiology into RNA medicines with Graham Dempsey of Quiver Bioscience

Value of the Information & Strength of the Argument

The value of the information is high, as it provides insights into the application of RNA therapeutics for neurological disorders, a cutting-edge area. The argumentation is solid, with Dempsey explaining the scientific rationale behind Quiver’s approach, including the genetic validation of targets and the use of electrophysiology to measure drug effects. He acknowledges the challenges and limitations, such as the difficulty of developing small molecules for Nav1.7 and the need for careful delivery methods. The discussion is well-structured and evidence-based, though it primarily reflects the company’s perspective.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is good, with references to well-established concepts like Nav1.7 genetics and ASO mechanisms. However, the episode does not cite specific studies or publications, and the only source provided is the company’s website. The title accurately reflects the content, which is focused on RNA medicines for brain physiology. The discussion is technically detailed but accessible, and the claims are consistent with current scientific understanding.

The title accurately reflects the content, which focuses on using RNA medicines to target brain physiology, as discussed with Graham Dempsey.

8/10

The discussion is led by an expert in the field, providing detailed and technically accurate explanations of complex topics such as antisense oligonucleotides, ion channels, and disease modeling. The claims are consistent with established scientific knowledge, and the guest's expertise lends credibility. However, the content is largely promotional for the company, and specific data or references are not provided in the episode.

• 00:00Intro to The Genetics Podcast
• 01:00Welcome to Graham
• 01:31The motivations and mission driving Quiver Bioscience
• 04:49Quiver’s approach to targeting the brain for neurological disease
• 07:19Nav1.7 as a lead pain program and the mechanisms of pain signaling
• 12:58Patient population and unmet need in chronic pain
• 14:30The Dup15q neurodevelopmental program and recent clinical progress
• 18:42How the company chooses which diseases to pursue and why genetically validated pain and epilepsy programs lead the pipeline
• 21:58Modeling pain in a dish and how cellular electrophysiology reveals disease and drug effects
• 29:35Lessons from building a biotech company
• 32:01Today’s biotech climate and why Graham is optimistic
• 34:19Emerging delivery technologies that could unlock the next wave of oligonucleotide therapies
• 36:25How molecular shuttles cross the blood–brain barrier and the advantage of a dual target approach
• 39:57Graham’s path from aspiring sports medicine doctor to building light-based platforms in neuroscience
• 43:32Graham’s early exposure to biotech leadership and a formative encounter with Roy Vagelos
• 45:36Closing remarks

• Quiver Bioscience — Company website mentioned in the show notes as a resource for more information.

• Quiver Bioscience — The company's official website, which likely contains more detailed information about their pipeline and technology.